CONTINGENT REPAYABLE ADVANCES

A contingent repayable advance gives a CDR developer money before work begins and requires repayment only if the supported activity reaches a stated commercial result, such as earning product revenue or licensing the technology. If it fails, some or all support becomes grant-like. If it succeeds, the provider recovers money through a share of later revenue and can reuse it. Governments, international programmes, regional agencies or philanthropies issue the award and bear the initial risk. Unlike a loan, repayment is not fixed. Unlike a grant, commercial success creates an obligation. It does not purchase removals or pool investments.

The hardest decision is what counts as commercial success, because that event turns risk-tolerant public or philanthropic support into a repayment obligation. The agreement needs an auditable trigger such as product revenue or licensing income, rather than a vague declaration that a project worked. Other choices include eligible CDR work, recipient contributions, funding stages, repayment start, revenue share, repayment cap, intellectual property, audit rights and default. CDR eligibility still requires credible lifecycle accounting and safeguards. Repayment should leave enough cash for growth and later investors, and recovered money may either return to the provider or finance new awards.

This instrument can fund pilots and first commercial demonstrations that are too uncertain for conventional lenders and too close to market for a full grant. Because repayment depends on success, recipients can attempt technically risky work without immediate debt payments. A provider may recover and reuse part of its capital when projects earn revenue. Successful projects can also produce operating and cost evidence that helps later investors judge risk, although neither repayment nor follow-on finance is guaranteed.

An unclear success test can trigger disputes or repayment before a recipient has usable cash. A weak test may let firms hide revenue through licensing or related-party sales, while a large revenue share can deter later investors. Loose eligibility may finance emissions avoidance instead of removal. Public providers can lose most of a concentrated portfolio if several technologies fail together, and uncertain recoveries should never be treated as dependable budget income.

Evaluation should compare money advanced with technical progress, commercial revenue, repayments, write-offs and funds reused. Project operation and verified net removals should remain separate from forecasts. Repeated disputes, weak commercial progress, poor integrity evidence or repayment terms that deter follow-on finance would justify changes to eligibility, contracts or portfolio limits.

Engagement should test whether proposed technical and commercial milestones are realistic, whether later repayments leave enough cash for growth and whether the records can be audited. Evidence from developers, investors, accountants and tax specialists should help shape contracts. Lifecycle experts, affected communities, programme managers and independent auditors are needed to examine removal integrity, safeguards, award decisions and enforcement.

Any body able to make grants or programme investments and enforce repayment contracts can use the instrument. International and supranational programmes may fund cross-border portfolios. National, regional, state and municipal governments may act under their spending and innovation powers. Philanthropies can use their own capital through recoverable grants.